• Member News

Humans on a chip – the future for research and drug discovery

Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the NC3Rs combine forces to propel the UK into the race to advance organ on a chip technology

PredictImmune join the Babraham Research Campus community

Developer of pioneering tools for guiding treatment options in immune-mediated inflammatory diseases choose Babraham Research Campus as permanent base within the Cambridge Cluster

Crescendo Biologics Raises $70m in Series B Financing

Crescendo are delighted to be celebrating our $70 Million (€57 Million) Series B Financing with investment from new investors, Andera Partners and Quan Capital, and continuing support from existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures. The funds will be used to advance the development of our lead programme, CB307 a novel targeted T-cell engager which stimulates local activation of tumour-specific T-cells, and further expand our internal pipeline of Humabody® products.

Astex’s Harren Jhoti made Fellow of the Royal Society

Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.

Synpromics Awarded £1.9m Grant from Scottish Enterprise

Synpromics Ltd, the leader in gene control, today announced it has been awarded a £1.9m research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines.

Horizon Discovery appoints Terry Pizzie as Chief Executive Officer

Horizon Discovery Group plc is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.

Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe

Point-of-care test for detection of infection in patients on peritoneal dialysis available in France, Germany, Italy, The Netherlands, Austria and Switzerland

IONTAS and aTen Therapeutics announce collaboration to discover therapeutic oncology leads

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics Limited (aTen), a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, announced today that they have entered into a strategic collaboration. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen.

Domainex ranked as the fastest growing drug discovery CRO in Europe

Domainex, is proud to announce its inclusion in the second annual top 1000 list of Europe’s fastest growing companies, published by the Financial Times.

Porton Biopharma opens new facility to make more of its childhood cancer cure

In the latest phase of it development as a new UK biopharmaceutical company Porton Biopharma ltd has officially opened a new state of the art fermentation facility which will manufacture its principle product Erwinase®, used for the treatment of Acute Lymphoblastic Leukaemia.